PARIS – French regulators are investigating a phase I trial of small-molecule candidate BIA 10-2474 after one volunteer was pronounced brain dead and five others hospitalized with identical neurological symptoms at the University Hospital Center of Rennes in France, in what appears to be the worst clinical disaster since 2006's phase I study of monoclonal antibody TGN1412 put six healthy volunteers into intensive care.

PARIS – At the start of what promises to be a big year for nanomedicine developer Nanobiotix SA, of Paris, the company reported approval for its first clinical trial in the U.S. and a bold new program stepping into the fast-developing field of immuno-oncology.